Introduction
Cardiac troponins are the recommended biomarkers for diagnosing myocardial infarction (MI), including type 5 MI, which is associated with coronary artery bypass grafting (CABG) [1] . Over the last decade, studies of cardiac biomarkers for type 5 MI have therefore focused on troponins, with a paucity of literature about older biomarkers such as aspartate aminotransferase (AST). This has occurred in part because troponins have superior sensitivity, specificity and prognostic value in this context [2] [3] [4] [5] . However, one contemporary study reported post-operative AST levels independently predicted early and late mortality after CABG [6] , but this finding has not been reproduced in other recent studies [7] [8] [9] . Whether AST levels are related to post-operative complications has not been previously studied. Older studies from our centre identified a cutpoint for AST twice the upper limit of normal (ULN) to be associated with myocardial damage after cardiac surgery [10, 11] . We therefore assessed the prognostic utility of this cutpoint for post-operative AST levels to predict mortality and morbidity after CABG and compared AST with high-sensitivity troponin T (hs-TnT).
Methods
Ethics approval was attained from the ethics committee of our institution's research office. The study involved patients who underwent isolated CABG without concomitant valve surgery from July 2010 to June 2012 at Auckland City Hospital. Patients were included if they had AST levels measured within 48 h after CABG, which was routinely performed in the cardiovascular intensive care unit. Where several measurements were taken the highest level was recorded. The normal reference range for AST is b45 U/L. This was compared to hs-TnT levels routinely measured 12-24 h after surgery, which has a 99% upper reference limit (URL) of 14 ng/L. 
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Definitions for pre-operative characteristics are as follows. Angina and dyspnea were graded using the Canadian Cardiovascular Society Classification (CCS) and the New York Heart Association Functional Classification (NYHA), respectively. Critical pre-operative state involved patients who required inotrope, ventilator and/or intra-aortic balloon pump (IABP) support during the hospital admission prior to surgery. Hypertension referred to a previous formal diagnosis, being prescribed medications to reduce blood pressure or any measurement of over 140/90 mmHg pre-operatively. Stroke was defined as neurological deficit that persisted over 24 h as a result of disturbance of cerebral blood supply. Peripheral vascular disease included claudication, ankle brachial index b0.9, imaging evidence of N 50% stenosis in any peripheral artery, a peripheral vascular intervention or amputation for arterial insufficiency. Chronic respiratory diseases included a previous formal diagnosis, use of inhaled corticosteroids for respiratory symptoms or forced expiratory volume in 1 s (FEV1) b80% on spirometry. The number of major coronary vessels with N 50% stenosis was recorded. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet and Renal Disease equation and the last serum creatinine measurement pre-operatively. EuroSCORE I and II were calculated to estimate operative risk [12, 13] . The type and number of bypass grafts and duration of operation, cardiopulmonary bypass and aortic cross-clamps were recorded.
Mortality data were obtained from New Zealand's national registry up until 30 June 2014. Five post-operative complications as defined by the Society of Thoracic Surgeon's (STS) score and their composite were determined, including permanent stroke (acute neurological deficit N24 h due to cerebral blood supply disturbance), renal failure (new dialysis requirement or increase of creatinine to N4.0 mg/dL and N 3 times last pre-operative level), prolonged ventilation N 24 h, deep sternal wound infection and return to theatre for any reason [14] . Peri-operative MI was defined according to the Third Universal Definition for type 5 MI [1] , including troponin increase to more than 10 times the 99th percentile URL of the assay and new signs of infarction on ECG, echocardiogram, coronary angiogram or magnetic resonance imaging. The pre-specified outcomes for analyses were 30-day mortality, long-term mortality during follow-up and composite morbidity.
Statistical analyses
We pre-specified dividing patients into two groups based on a cutpoint of 90 U/L, i.e. twice the ULN, for analyses. Mann-Whitney U test and Fisher's exact test were used for univariate analyses for continuous (presented as mean/standard deviation) and categorical variables (percentage/frequency), respectively. Kaplan-Meier curves and log-rank (Mantel-Cox) test was used for univariate longitudinal analyses. Receiver-operative characteristics analysis was used to calculate c-statistic and 95% confidence interval (95% CI). Multivariable analyses incorporated variables with P b 0.10 in univariate analyses, using logistic regression to calculate odds ratios (OR) for crosssectional outcomes and Cox proportional hazards regression used to calculate hazards ratios (HR) for mortality. AST and hs-TnT as continuous parameters, and separately AST N90 U/L were included in the multivariable models for outcomes. All tests were two-tailed with significance level set at 0.05. Statistical software used were SPSS (Version 17.0, SPSS Inc., Chicago, IL, USA) and Prism (Version 5, GraphPad Software, San Diego, CA, USA).
Results
A total of 818 patients underwent isolated CABG during the twoyear study period, of which 804 had post-operative AST measurements within 48 h included in the study, 555 (69.0%) of whom had AST in the normal range b45 U/L. Median post-operative AST levels was 37 U/L (lower quartile 30, upper quartile 48). Table 1 presents the baseline characteristics for subjects with postoperative AST≤ and N 90 U/L. Those with AST N90 U/L (n = 49, 6.1%) had a higher proportion of women (40.8% vs. 19.2%, P = 0.001) and higher prevalence of CCS class IV angina (51.0% vs. 36.7%, P = 0.049).
Operative and post-operative data are shown in Table 2 . AST N90 U/L was associated with longer operation time (229 vs. 215 min, P = 0.037). In univariate analyses for outcomes, AST N90 U/L was associated with 30-day mortality (OR 12.1, 95% CI 3.70-39.8, P b 0.001), composite morbidity (OR 3.51, 95% CI 1.92-6.40, P b 0.001), ventilation N 24 h (OR 3.58, 95% CI 1.90-6.77, P b 0.001), peri-operative MI (OR 2.78, 95% CI 1.28-6.02, P = 0.01) and new atrial fibrillation (OR 1.96, 95% CI 1.06-3.62, P = 0.032). Fig. 1 illustrates survival over a mean follow-up of 2.8 ± 0.6 years. Patients with AST N90 U/L had significantly greater long-term mortality (HR 19.8, 95% CI 3.36-117, P b 0.001). One-year survival was 87.3% for patients with AST N90 U/L compared to 98.0% for patients AST b90 U/L. Most of the difference was within the first month. Results from the receiver-operative characteristics analyses are listed in Table 3 Table 4 shows the variables with P b 0.10 in multivariable analyses. Female sex, CCS Class IV angina and operation time were independent predictors of AST N90 U/L. AST N 90 U/L was independently associated with 30-day mortality (OR 12.0, 95% CI 2.99-47.9, P b 0.001), longterm mortality (OR 12.0, 95% CI 1.69-34.8, P b 0.001) and composite morbidity (OR 3.31, 95% CI 1.56-7.02, P = 0.002). If post-operative complications was introduced into the model, AST N 90 U/L remained an independent predictor of 30-day mortality (OR 7.61, 95% CI 1.69-34.8, P = 0.008).
Post-operative AST, as a continuous parameter when hs-TnT was adjusted for, independently predicted 30-day mortality (OR 1.14, 95% CI 1.04-1.25, P = 0.004) and long-term mortality (HR 1.08, 95% CI 1.01-1.16, P = 0.031) but not composite morbidity (OR 1.03, 95% CI 0.962-1.10, P = 0.409). Hs-TnT as a continuous parameter predicted AST = aspartate aminotransferase; CCS = Canadian Cardiovascular Society Classification; eGFR = Estimated glomerular filtration rate; hs-TnT = high-sensitivity troponin T; NYHA = New York Heart Association Functional Classification. ⁎ Critical pre-operative state involved patients who required inotrope, ventilator and/or intra-aortic balloon pump (IABP) support during the hospital admission prior to surgery. composite morbidity (P b 0.001) but not 30-day mortality (P = 0.429) or long-term mortality (P = 0.987).
Discussion
The novel finding of our study is that elevated AST levels independently predicts 30-day mortality and long-term mortality after isolated CABG even when adjusted for hs-troponin. It was also independently associated with composite morbidity after adjustment for baseline variables.
AST is an enzyme that catalyses aspartate and α-ketoglutarate to oxaloacetate and glutamate, and is mainly found in the liver, followed by the heart and other organs including skeletal muscle, brain and kidneys. AST peaks around 24-36 h post-operatively after CABG, and remains elevated for 3-5 days [15, 16] . The wide tissue distribution impairs its specificity for myocardial damage and therefore MI diagnosis. However, AST might be a prognostic indicator in cardiac surgery because non-cardiac sources of AST rise such as liver or skeletal muscle can also reflect impaired cardiac function, ischaemia and decreased tissue perfusion. We routinely measure AST after cardiac surgery because of earlier work published from our centre showing AST's correlation with myocardial damage and prognosis in this context [10, 11] .
A few studies have found AST to be independently associated with mortality after CABG [6, 17] . However, other smaller and underpowered studies did not find an independent association [7] [8] [9] . Early studies showed that AST levels remained normal in the majority of patients after CABG [18, 19] . One study found 71.8% of patients having AST b 50 U/L post-operatively, similar to the 68.9% of patients having normal AST b45 U/L in our study [6] .
Although AST N 90 U/L predicted both 30-day and long-term mortality in our study, the main difference in mortality was in the first 30 days, whereas late mortality was not significantly different. Similar results have been reported in other studies [6, 17] . This was true even after adjusting for post-operative complications including ventilation N 24 h and return to theatre, as well as hs-TnT, suggesting its prognostic value for early mortality has a different pathophysiology.
The optimal cutpoint for AST rise for predicting mortality after CABG would be expected to differ from that for hs-troponin. The recent third universal definition for type 5 MI, which involves dual criteria of elevated biomarkers, preferably troponin, with new signs of infarction on electrocardiogram, echocardiogram, coronary angiogram or cardiac magnetic resonance imaging and arbitrarily set the biomarker threshold at 10 times 99th percentile URL [1] . This threshold is supported by a subsequent study using high-sensitivity troponin T of N140 ng/L, i.e., 10 times 99th percentile URL with ECG and/or echocardiographic criteria [20] . Other studies of isolated troponin rise in CABG have found much higher optimal cutpoints of 50-160 times [21, 22] . Our study's cutpoint of AST N90 U/L is 2 times the ULN and independently predicted 30-day and long-term mortality. Other studies have reported lower thresholds of 3-6 times ULN for AST [6, 7, 17] .
Our results also show that AST independently predicted composite morbidity in our study although not after hs-TnT adjustment. AST N90 U/L was also associated with higher rates of ventilation N24 h, new atrial fibrillation and MI.
Limitations
This is a single-centre retrospective study. We did not have serial AST data for a significant proportion of patients to assess the dynamic profile of post-operative AST levels, and did not measure AST preoperatively. Other liver enzymes were not routinely measured for assessment of liver damage causing the elevation of AST. Duration of follow-up was short given that this was a contemporary cohort, and other outcomes during follow-up were not obtained.
Conclusion
Post-operative AST levels predict mortality and morbidity after CABG. AST is a useful prognostic biomarker for adverse outcomes after CABG even though it is not specific for myocardial damage.
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